SOURCE ARCHIVE · ORIGINAL LINKS INCLUDED
Johnson & Johnson finalized the $1 billion acquisition of Firefly Bio, Inc. to expand its oncology portfolio with the Firelink™ degrader antibody conjugate platform, targeting difficult-to-treat solid tumors including...
Johnson & Johnson will collaborate with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, with a $2.58 billion acquisition option and $785 million initial payments.
Johnson & Johnson announced FDA De Novo authorization for its OTTAVA™ Robotic Surgical System, the first table-integrated soft tissue robotic system, approved for multiple general surgery procedures in the U.S.
Johnson & Johnson reported Q2 2026 sales exceeding $25 billion and raised its full-year revenue guidance above $100 billion, marking the company’s first annual revenue target surpassing that threshold in its 140-year...
Johnson & Johnson announced FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, enabling electrophysiologists to use both radiofrequency and pulsed field energy in a single catheter for cardiac ablation...
Johnson & Johnson will invest over $1 billion to expand its U.S. Vision operations in Jacksonville, Florida, including a new distribution facility and advanced manufacturing capabilities for ACUVUE® contact lenses.
Johnson & Johnson reported Phase 3 MonumenTAL-3 study results showing TALVEY plus DARZALEX FASPRO reduced disease progression or death risk by up to 72% versus standard therapy in relapsed/refractory multiple myeloma.
Johnson & Johnson’s IMAAVY (nipocalimab-aahu) showed durable hemoglobin improvement and rapid onset in a Phase 2/3 wAIHA study, with three times more responders than placebo by 24 weeks.
Johnson & Johnson presented Phase 2 trial data showing nipocalimab reduced disease-driving autoantibodies in Sjögren’s disease, with stronger effects in patients with elevated IgG levels.
Johnson & Johnson reported pivotal trial results showing subcutaneous RYBREVANT FASPRO™ achieved a 42% response rate in advanced head and neck cancer, with over a third of responders experiencing complete responses.